Humacyte Inc 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ______ to ______.Commission File Number: 001-39532 Humacyte, Inc.(Exact name of registrant as specified in its charter) Securities registered pursuant to 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the ExchangeAct. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo As of May 11, 2026, 222,019,108 shares of common stock, par value $0.0001, were issued and outstanding. Humacyte, Inc.Quarterly Report on Form 10-QTable of Contents Page No.PART I – FINANCIAL INFORMATIONItem 1.Financial Statements5Condensed Consolidated Balance Sheets (unaudited)5Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited)6Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited)7Condensed Consolidated Statements of Cash Flows (unaudited)8Notes to Condensed Consolidated Financial Statements (unaudited)9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations46Item 3.Quantitative and Qualitative Disclosures About Market Risk59Item 4.Controls and Procedures59PART II – OTHER INFORMATIONItem 1.Legal Proceedings60Item 1A.Risk Factors60Item 2.Unregistered Sales of Equity Securities and Use of Proceeds61Item 3.Defaults Upon Senior Securities61Item 4.Mine Safety Disclosures61Item 5.Other Information61Item 6.Exhibits62SIGNATURES63 FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements that involve substantial risksand uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995,Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) arestatements that are not historical facts and involve a number of risks and uncertainties. These statements include, without limitation,statements regarding the financial position, business strategy and the plans and objectives of management for future operations.These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Suchstatements can be identified by the fact that they do not relate strictly to historical or current facts. When used therein, words suchas “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,”“predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absenceof these words does not mean that a statement is not forward-looking. Such statements are based on the beliefs of, as well asassumptions made by and information currently available to, our management. Forward-looking statements may include, for example, statements about: •our plans and ability to commercialize Symvess®(acellular tissue engineered vessel-tyod or “ATEV”) and, if approved byregulatory authorities, our product candidates, successfully and on our anticipated timelines;•the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, ifapproved by regulatory authorities, our product candidates;•our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates, in sufficientquantities to satisfy our clinical trial and commercial needs;•the expected size of the target populations for Symvess and, if approved by regulato